text:
Department of Health and Human Services
Participating Organizations
National Institutes of Health (NIH), (http://www.nih.gov/)
Centers for Disease Control and Prevention (CDC), (http://www.cdc.gov/)
Food and Drug Administration (FDA), (http://www.fda.gov/)
Components of Participating Organizations
National Cancer Institute (NCI/NIH), (http://www.cancer.gov/)
National Eye Institute (NEI/NIH), (http://www.nei.nih.gov/)
National Heart, Lung, and Blood Institute (NHLBI/NIH), (http://www.nhlbi.nih.gov/index.htm)
National Human Genome Research Institute (NHGRI/NIH), (http://www.genome.gov/)
National Institute on Aging (NIA/NIH), (http://www.nia.nih.gov/)
National Institute on Alcohol Abuse and Alcoholism (NIAAA/NIH), (http://www.niaaa.nih.gov/)
National Institute of Allergy and Infectious Diseases (NIAID/NIH), (http://www3.niaid.nih.gov/)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS/NIH), (http://www.niams.nih.gov/)
National Institute of Biomedical Imaging and Bioengineering (NIBIB/NIH), (http://www.nibib.nih.gov/)
National Institute of Child Health and Human Development (NICHD/NIH), (http://www.nichd.nih.gov/)
National Institute on Deafness and Other Communication Disorders (NIDCD/NIH), (http://www.nidcd.nih.gov/)
National Institute of Dental and Craniofacial Research (NIDCR/NIH), (http://www.nidcr.nih.gov/)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH), (http://www.niddk.nih.gov/)
National Institute on Drug Abuse (NIDA/NIH), (http://www.nida.nih.gov/)
National Institute of Environmental Health Sciences (NIEHS/NIH), (http://www.niehs.nih.gov/)
National Institute of General Medical Sciences (NIGMS/NIH), (http://www.nigms.nih.gov/)
National Institute of Mental Health (NIMH/NIH), (http://www.nimh.nih.gov/)
National Institute of Neurological Disorders and Stroke (NINDS/NIH), (http://www.ninds.nih.gov/)
National Institute of Nursing Research (NINR/NIH), (http://www.ninr.nih.gov/)
National Library of Medicine (NLM/NIH), (http://www.nlm.nih.gov/)
National Center for Complementary and Alternative Medicine (NCCAM/NIH), (http://nccam.nih.gov/)
National Center on Minority Health and Health Disparities (NCMHD/NIH), (http://ncmhd.nih.gov/)
National Center for Research Resources (NCRR/NIH), (http://www.ncrr.nih.gov/)
National Institute for Occupational Safety and Health (NIOSH/CDC), (http://www.cdc.gov/niosh/homepage.html)
National Center on Birth Defects and Developmental Disabilities (NCBDDD/CDC), (http://www.cdc.gov/ncbddd/)
National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP/CDC), (http://www.cdc.gov/nccdphp/)
National Center for Environmental Health (NCEH/CDC), (http://www.cdc.gov/nceh/)
National Center for Injury Prevention and Control (NCIPC/CDC), (http://www.cdc.gov/ncipc/)
Center for Biologics Evaluation and Research (CBER/FDA), (http://www.fda.gov/cber/)
Center for Drug Evaluation and Research (CDER/FDA), (http://www.fda.gov/cder/)
Center for Food Safety and Applied Nutrition (CFSAN/FDA), (http://www.foodsafety.gov/list.html)
Center for Veterinary Medicine (CVM/FDA), (http://www.fda.gov/cvm/)
Office of Orphan Products Development (OPD/FDA), (http://www.fda.gov/orphan/)
Title: Small Business Innovation Research Program Parent Announcement (SBIR [R43/R44]): Electronic Submission of Grant Applications through Grants.gov
Announcement Type
Update: The following update relating to this announcement has been issued:
NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 (R&R) forms and Grants.gov SBIR/STTR Application Guide. APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT.
This FOA must be read in conjunction with the application guidelines included with this announcement in Grants.gov Apply for Grants (hereafter called Grants.gov/Apply).
A registration process is necessary before submission and should be started at least two weeks in advance of the planned submission. See Section IV.
Two steps are required for on time submission:
1) The application must be submitted to grants.gov by 8:00 p.m. Eastern Time on the submission date (see Key Dates below)
2) Applicants must complete a verification step in the eRA Commons within two business days of notification from NIH. Note: Since email can be unreliable, it is the responsibility of the applicant to periodically check on their application status in the Commons.
This FOA is for ONLY the standard NIH, CDC, and FDA SBIR submission date of December 1, 2005 and, for AIDS/AIDS-related applications, for the January 2, 2006 date.
Program Announcement (PA) Number:
Catalog of Federal Domestic Assistance Number(s)
93.061, 93.063, 93.067, 93.103, 93.113, 93.114, 93.115, 93.118, 93.121, 93.135, 93.136, 93.143, 93.161, 93.172, 93.173, 93.184, 93.185, 93.197, 93.206, 93.208, 93.213, 93.233, 93.242, 93.262, 93.268, 93.273, 93.279, 93.283, 93.286, 93.307, 93.361, 93.389, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.846, 93.847, 93.848, 93.849, 93.853, 93.855, 93.856, 93.859, 93.865, 93.866, 93.867, 93.879, 93.941, 93.942, 93.943, 93.947, 93.978
Key Dates
Release Date: October 17, 2005
Letters of Intent Receipt Date: Not applicable.
Application Submission Date: December 1, 2005
AIDS Application Submission Date: January 2, 2006
Peer Review Date(s): February-March, 2006
Council Review Date(s): May-June, 2006
Earliest Anticipated Start Date: July 2006
Additional Information To Be Available Date (Activation Date): Not Applicable
Expiration Date: January 4, 2006
Due Dates for E.O. 12372
Not applicable
Additional Overview Content
Executive Summary
The purpose of this FOA from NIH, CDC, and FDA is to invite eligible United States small business concerns (SBCs) to submit SBIR Phase I, Phase II, and Fast-Track grant applications through Grants.gov. SBIR Fast-Track grant applications are accepted by the NIH ONLY.
Part I Overview Information
Part II Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2.Cost Sharing or Matching
3. Other - Special Eligibility Criteria
Section IV. Application and Submission Information
1. Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Submission, Review, and Anticipated Start Dates
1. Letter of Intent
B. Sending an Application to the NIH
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review Considerations
C. Sharing Research Data
D. Sharing Research Resources (Not in this document.)
3. Anticipated Announcement and Award Dates
Section VI. Award Administration Information
1. Award Notices
2. Administrative and National Policy Requirements
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research and Financial/Grants Management Contact(s)
2. Peer Review Contact(s)
Section VIII. Other Information - Required Federal Citations
1. Research Objectives
See NIH, CDC, and FDA SBIR/STTR Program Descriptions and Research Topics.
The research topics shown in the solicitation cited above represent program areas that may be of interest to applicant small business concerns in the development of projects that have potential for commercialization. Small business concerns are encouraged to submit SBIR grant applications in these areas.
In addition to the general research areas described in the NIH, CDC, and FDA SBIR/STTR Program Descriptions and Research Topics (https://grants.nih.gov/grants/funding/sbirsttr1/2005-2_SBIR-STTR-topics.doc), some HHS awarding components have identified additional, specific SBIR funding opportunities of potential interest to SBCs, as listed in the RFA, PA, PAR, and PAS announcements below. If you know of other FOAs with SF424 (R&R) requirements, but do not find them listed below, please search for those in Grants.gov/FIND as a separate FOA.
Applicants interested in the specific opportunities listed in the table below must use the application package from this parent SBIR FOA in Grants.gov/FIND (i.e., PA-06-006) to apply. If applicable, applicants should then reference one of the opportunities below in the Cover Letter component of the SF424 (R&R) Application package to be considered under the specific funding opportunity.
Additional Research Topics
Molecular Libraries Screening Instrumentation – SBIR/STTR
Drug Delivery Systems for Orofacial Disease (SBIR/STTR)
Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, Blood, and Aging Diseases (SBIR/STTR)
See Section VIII, Other Information - Required Federal Citations for policies related to this announcement.Section II. Award Information
1. Mechanism(s) of Support
This funding opportunity will use the SBIR (R43/R44) grant mechanisms. Applications may be submitted for support as Phase I, Phase II, or Fast-Track grants as described in the SF424 (R&R) SBIR/STTR Application Guide (MS Word or PDF).
A parallel funding opportunity announcement of identical scientific scope (PA-06-007) utilizes the STTR (R41/R42) grant mechanisms. Applicants may not simultaneously submit identical/essentially identical applications under both this funding opportunity and another HHS funding opportunity announcement, including the HHS STTR Parent FOA (PA-06-007) or other HHS FOAs.
Phase II applications in response to this funding opportunity will only be accepted as competing renewals (formerly "competing continuations") of previously funded Phase I SBIR awards. The Phase II must be a logical extension of the Phase I research but not necessarily as a Phase I project supported in response to this funding opportunity.
The applicant SBC will be solely responsible for planning, directing, and executing the proposed project. Future unsolicited, competing renewal applications based on this project will compete with all SBIR applications and will be reviewed according to the customary peer review procedures. Applications that are not funded in the competition described in this FOA may be submitted as RESUBMISSION applications through Grants.gov Apply using the standard NIH, CDC, and FDA SBIR submission dates of April 1, August 1, and December 1 (or January 2, May 1, or September 1 for AIDS and AIDS-related SBIR applications).
This funding opportunity uses just-in-time concepts. The modular budget format is no longer accepted for SBIR grant applications. Applicants must complete and submit detailed budget requests using the SF424 (R&R) Budget Component found in the application package attached to this announcement in Grants.gov/Apply.
2. Funds Available
The SF424 (R&R) SBIR/STTR Application Guide (MS Word or PDF) indicates the statutory guidelines of funding support and project duration periods for SBIR Phase I and Phase II awards.
1. Eligible Applicants
1.A. Eligible Institutions
Only United States small business concerns (SBCs) are eligible to submit SBIR applications. A small business concern is one that, at the time of award, for both Phase I and Phase II awards, meets all of the following criteria:
1. Is independently owned and operated, is not dominant in the field of operation in which it is proposing, has a place of business in the United States and operates primarily within the United States or makes a significant contribution to the US economy, and is organized for profit.
2. Is (a) at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States, or (b) for SBIR only, it must be a for-profit business concern that is at least 51% owned and controlled by another for-profit business concern that is at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States.
3. Has, including its affiliates, an average number of employees for the preceding 12 months not exceeding 500, and meets the other regulatory requirements found in 13 C.F.R. Part 121. Business concerns are generally considered to be affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both.
Control can be exercised through common ownership, common management, and contractual relationships. The term "affiliates" is defined in greater detail in 13 C.F.R. 121.103. The term "number of employees" is defined in 13 C.F.R. 121.106.
A business concern may be in the form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust, or cooperative. Further information may be obtained at http://sba.gov/size, or by contacting the Small Business Administration's Government Contracting Area Office or Office of Size Standards.
One of the circumstances that would lead to a finding that an organization is controlling or has the power to control another organization involves sharing common office space and/or employees and/or other facilities (e.g., laboratory space). Access to special facilities or equipment in another organization is permitted (as in cases where the awardee organization has entered into a subcontractual agreement with another organization for a specific, limited portion of the research project). However, research space occupied by an SBIR awardee organization must be space that is available to and under the control of the SBIR/STTR awardee for the conduct of its portion of the proposed project.
Title 13 C.F.R. 121.3 also states that control or the power to control exists when "key employees of one concern organize a new concern ... and serve as its officers, directors, principal stockholders, and/or key employees, and one concern is furnishing or will furnish the other concern with subcontracts, financial or technical assistance, and/or other facilities, whether for a fee or otherwise." Where there is indication of sharing of common employees, a determination will be made on a case-by-case basis of whether such sharing constitutes control or the power to control.
For purposes of the SBIR program, personnel obtained through a Professional Employer Organization or other similar personnel leasing company may be considered employees of the awardee. This is consistent with SBA's size regulations, 13C.F.R. 121.106 – Small Business Size Regulations.
All SBIR grant applications will be examined with the above eligibility considerations in mind. If it appears that an applicant organization does not meet the eligibility requirements, NIH will request a size determination by the SBA. If eligibility is unclear, NIH will not make an SBIR award until the SBA provides a determination.
1.B. Eligible Individuals
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs.
Under the SBIR program, for both Phase I and Phase II, the primary employment of the PD/PI must be with the small business concern at the time of award and during the conduct of the proposed project. Primary employment means that more than one half of the PD/PI's time is spent in the employ of the small business concern. Primary employment with a small business concern precludes full-time employment at another organization. Occasionally, deviations from this requirement may occur. Such deviations must be approved in writing by the grants management officer after consultation with the NIH SBIR/STTR Program Coordinator.
As defined in 42 C.F.R. 52, the PD/PI is the "single individual designated by the grantee in the grant application … who is responsible for the scientific and technical direction of the project." When the proposed PD/PI clearly does not have sufficient qualifications to assume this role, the application is not likely to receive a favorable evaluation.
If the application has the likelihood for funding, the awarding component will require documentation to verify the eligibility of the PD/PI, if at the time of submission of the application, the PD/PI is a less-than-full-time employee of the small business concern, is concurrently employed by another organization, or gives the appearance of being concurrently employed by another organization, whether for a paid or unpaid position.
If the PD/PI is employed or appears to be employed by an organization other than the applicant organization in a capacity such as Research Fellow, Consultant, Adjunct Professor, Clinical Professor, Clinical Research Professor, or Associate, a letter must be provided by each employing organization confirming that, if an SBIR grant is awarded to the applicant small business concern, the PD/PI is or will become a less-than-half-time employee of such organization and will remain so for the duration of the SBIR project. If the PD/PI is employed by a university, such a letter must be provided by the Dean's office or equivalent; for other organizations, the letter must be signed by a corporate official.
This requirement applies also to those individuals engaged currently as the PD/PI on an active SBIR project. All current employment and all other appointments of the PD/PI must be identified in his or her "Biographical Sketch" required as part of the application. Be certain that correct beginning and ending dates are indicated for each employment record listed.
2. Cost Sharing or Matching
This program does not require cost sharing as defined in the current NIH Grants Policy Statement.
3. Other-Special Eligibility Criteria
The NIH will accept as many "different" applications as the applicant organization (SBC) chooses. However, the NIH will not accept similar grant applications with essentially the same research focus from the same applicant organization. This includes derivative or multiple applications that propose to develop a single product, process or service that, with non-substantive modifications, can be applied to a variety of purposes. Applicants may not simultaneously submit identical/essentially identical applications under both this funding opportunity and another HHS funding opportunity, including the HHS parent STTR (PA-06-007).
To download an Application Package and Instructions for completing the SF424 Research and Related (R&R) Forms for this FOA, link to http://www.grants.gov/Apply and follow the directions provided on that site.
A one-time registration is required for institutions at both:
PD/PIs should work with their institutions/organizations to make sure they are registered in the NIH Commons.
Several additional separate actions are required before an applicant SBC can submit an application through Grants.gov. See "Preparing for Electronic Submission" at http://era.nih.gov/ElectronicReceipt/preparing.htm for more details.
Several of the steps of the registration process could take up to two weeks. Therefore, applicants should immediately check with their business official to determine whether their small business is already registered in both Grants.gov and the Commons.
1. Request Application Information
Applicants must download the SF424 (R&R) application forms and instructions for this FOA through the Grants.gov Apply Web site.
Note: Only the forms package directly attached to a specific FOA can be used. You will not be able to use any other SF424 (R&R) forms (e.g., sample forms, forms from another FOA), although some of the "Attachment" files may be useable for more than one FOA.
For further assistance contact GrantsInfo, Telephone (301) 710-0267, Email: email@example.com.
Telecommunications for the hearing impaired: TTY 301-451-5936.
2. Content and Form of Application Submission
Prepare all SBIR applications using the SF424 (R&R) application forms and SF424 (R&R) SBIR/STTR Application Guide (MS Word or PDF) instructions.
The SF424 (R&R) application is comprised of data arranged in separate components. Some components are required, others are optional. The forms package associated with this announcement in Grants.gov Apply will include all applicable components, required and optional. A completed application in response to this announcement will include the following components.
Required Components:
SF424 (R&R) (Cover component)
Research & Related Project/Performance Site Locations
Research & Related Other Project Information
Research & Related Senior/Key Person
Research & Related Budget
PHS398 Cover Page Supplement
PHS398 Research Plan
PHS398 Checklist
SBIR/STTR Information
Optional Components:
PHS398 Cover Letter File
Research & Related Subaward Budget Form
3. Submission Dates and Times
See Section IV.3.A for details.
3.A. Submission, Review, and Anticipated Start Dates
Letter of Intent Receipt Date: A letter of intent is not required for this funding opportunity.
Application Submission Date: December 1, 2005
AIDS Application Submission Date: January 2, 2006
Peer Review Date: February-March, 2006
Council Review Date: April-May, 2006
Earliest Anticipated Start Date: July 2006
3.A.1. Letter of Intent
A letter of intent is not required for this funding opportunity.
3.B. Sending an Application to the NIH
Applications in response to this FOA may only be submitted to Grants.gov through Grants.gov Apply. PAPER APPLICATIONS WILL NOT BE ACCEPTED.
3.C. Application Processing
Applications may be submitted to Grants.gov on or after November 7, 2005 (i.e., the Open Date on Grants.gov) and must be submitted no later than 8:00 p.m. Eastern Time on the application submission date described above (Section IV.3.A.). If an application is not submitted by that date, the application may be delayed in the review process or not reviewed.
Upon receipt, applications will be transferred from Grants.gov to the NIH Electronic Research Administration process for validation. Both the PD/PI and the Signing Official for the organization must verify the submission via Commons within 2 business days of notification of the NIH validation.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review (CSR), NIH. Incomplete applications will not be reviewed.
The NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial merit review unless the applicant withdraws the pending application. The NIH will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of an application already reviewed with substantial changes, but such application must include an Introduction addressing the previous critique. Note such an application is considered a "resubmission" for the SF424 (R&R).
There will be an acknowledgement of receipt of applications from Grants.gov and the Commons. Information related to the assignment of an application to a Scientific Review Group is also in the Commons.
4. Intergovernmental Review
This initiative is not subject to intergovernmental review.
5. Funding Restrictions
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-Award Costs are allowable. A grantee organization may, at its own risk and without NIH prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new or competing renewal award if such costs: are necessary to conduct the project, and would be allowable under the grant, if awarded, without NIH prior approval. If specific expenditures would otherwise require prior approval, the grantee must obtain NIH approval before incurring the cost. NIH prior approval is required for any costs to be incurred more than 90 days before the beginning date of the initial budget period of a new or competing renewal award.
The incurrence of pre-award costs in anticipation of a competing or non-competing award imposes no obligation on NIH either to make the award or to increase the amount of the approved budget if an award is made for less than the amount anticipated and is inadequate to cover the pre-award costs incurred. NIH expects the grantee to be fully aware that pre-award costs result in borrowing against future support and that such borrowing must not impair the grantee's ability to accomplish the project objectives in the approved time frame or in any way adversely affect the conduct of the project. See the NIH Grants Policy Statement.
6. Other Submission Requirements
All application instructions outlined in the SF424 (R&R) SBIR/STTR Application Guide (MS Word or PDF) are to be followed, with the following requirements.
Note: While each section of the Research Plan needs to eventually be uploaded separately as a PDF attachment, applicants are encouraged to construct the Research Plan as a single document, separating sections into distinct PDF attachments just before uploading the files. This approach will enable applicants to better monitor formatting requirements such as page limits.
SBIR Phase I applications:
There is no further limitation on the total number of pages for the entire Phase I application; however, applicants are encouraged to be succinct.
SBIR Phase II applications:
SBIR Fast-Track applications
Plan for Sharing Research Data
Applicants requesting $500,000 or more in direct costs in any year should include a brief one paragraph description of how final research data will be shared, or explain why data-sharing is not possible. The specific nature of the data to be collected will determine whether or not the final dataset may be shared. If the final data are not amenable to sharing, for example, if they are proprietary, this must be explained in the application. The Small Business Act requires NIH to protect from disclosure and nongovernmental use all SBIR and STTR data developed from work performed under an SBIR and STTR funding agreement for a period of 4 years after the closeout of either a Phase I or Phase II grant unless NIH obtains permission from the awardee to disclose these data. The data rights protection period lapses only upon expiration of the protection period applicable to the SBIR and STTR award, or by agreement between the small business concern and NIH. Applicants are encouraged to discuss their data-sharing plan with the Institute/Center staff likely to accept assignment of their application.
The reasonableness of the data sharing plan or the rationale for not sharing research data may be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score. For more information on data sharing see https://grants.nih.gov/grants/policy/data_sharing/ and https://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm. (See FAQ #13.)
Sharing Research Resources
NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (NIH Grants Policy Statement https://grants.nih.gov/archive/archive/grants/policy/nihgps_2003/index.htm and https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm#_Toc54600131). Investigators responding to this funding opportunity should include a plan for sharing research resources addressing how unique research resources will be shared or explain why sharing is not possible.
The adequacy of the resources sharing plan and any related data sharing plans will be considered by Program staff of the funding organization when making recommendations about funding applications. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each Non-Competing Grant Progress Report (PHS 2590. See Section VI.3. Reporting.
1. Criteria
Only the review criteria described below will be considered in the review process.
2. Review and Selection Process
Applications submitted for this funding opportunity will be assigned to the Institutes/Centers (ICs) on the basis of established PHS referral guidelines.
Appropriate scientific review groups convened in accordance with the standard NIH peer review procedures (http://www.csr.nih.gov/refrev.htm) will evaluate applications for scientific and technical merit.
As part of the initial merit review, all applications will:
Applications submitted in response to this funding opportunity will compete for available funds with all other recommended SBIR applications. The following will be considered in making funding decisions:
The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. In the written comments, reviewers will be asked to discuss the following aspects of the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. The scientific review group will address and consider each of these criteria in assigning the application's overall score, weighting them as appropriate for each application.
The application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score.
All SBIR Applications
Significance: Does the proposed project have commercial potential to lead to a marketable product, process or service? Does this study address an important problem? What may be the anticipated commercial and societal benefits that may be derived from the proposed research? If the aims of the application are achieved, how will scientific knowledge or clinical practice be advanced? What will be the effect of these studies on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Does the application lead to enabling technologies (e.g., instrumentation, software) for further discoveries? Will the technology have a competitive advantage over existing/alternate technologies that can meet the market needs?
Approach: Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Is the proposed plan a sound approach for establishing technical and commercial feasibility? Does the applicant acknowledge potential problem areas and consider alternative strategies? Are the milestones and evaluation procedures appropriate?
Innovation: Are the aims original and innovative? Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?
Investigator: Is the PD/PI appropriately trained and capable of coordinating and managing the proposed SBIR? Are the investigators and well suited to carry out this work? Does the investigative team bring complementary and integrated expertise to the project (if applicable)? Is the work proposed appropriate to the experience level of the PD/PI and other researchers, including consultants and subcontractors (if any)? Are the relationships of the key personnel to the small business and to other institutions appropriate for the work proposed?
Environment: Is there sufficient access to resources (e.g., equipment, facilities)? Does the scientific and technological environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support?
Phase II Applications In addition to the above review criteria:
1. How well did the applicant demonstrate progress toward meeting the Phase I objectives, demonstrating feasibility, and providing a solid foundation for the proposed Phase II activity?
2. Did the applicant submit a concise Commercialization Plan that adequately addresses the specific areas described in the SF424 (R&R) SBIR/STTR Application Guide (MS Word or PDF) and the SBIR/STTR Information component?
3. Does the project carry a high degree of commercial potential, as described in the Commercialization Plan?
Resubmission Applications (formerly "amended" applications)
In addition to the above criteria, the following criteria will be applied to resubmission applications.
1. Are the responses to comments from the previous SRG review adequate?
2. Are the improvements in the resubmission application appropriate?
Phase I/Phase II Fast-Track Application Review Criteria
For Phase I/Phase II Fast Track applications, the following criteria also will be applied:
1. Does the Phase I application specify clear, appropriate, measurable goals (milestones) that should be achieved prior to initiating Phase II?
2. Did the applicant submit a concise Commercialization Plan that adequately addresses the specific areas described in the SF424 (R&R) SBIR/STTR Application Guide (MS Word or PDF) and the SBIR/STTR Information component?
3. To what extent was the applicant able to obtain letters of interest, additional funding commitments, and/or resources from the private sector or non-SBIR/STTR funding sources that would enhance the likelihood for commercialization?
4. Does the project carry a high degree of commercial potential, as described in the Commercialization Plan?
Phase I and Phase II Fast-Track applications that satisfy all of the review criteria will receive a single rating.
For Fast-Track applications, the Phase II portion may not be funded until a Phase I final report and other documents necessary for continuation have been received and assessed by program staff that the Phase I milestones have been successfully achieved. Items 2-5 of the Research Plan may not exceed 25 pages. That is, the combined Phase I and Phase II plans for a Fast-track application (for items 2-5) must be contained within the 25-page limit.
Type 2 (Renewal) Phase II Competing Continuation Applications
In addition to the above review criteria described under ALL SBIR applications, the following items will be applied to ALL Type 2 Competing Continuation (Renewal) Phase II applications in the determination of scientific merit and the priority score.
1. Does the activity as proposed address issues related to Federal regulatory approval processes?
2. Did the applicant submit a concise Commercialization Plan that adequately addresses the specific areas described in the SF424 (R&R) SBIR/STTR Application Guide (MS Word or PDF) and the SBIR/STTR Information component?
3. Does the project carry a high degree of commercial potential as described in the Commercialization Plan?
2.A. Additional Review Criteria:
In addition to the above criteria, the following items will continue to be considered in the determination of scientific merit and the priority score:
Protection of Human Subjects from Research Risk: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed. See item 6 of the Research Plan component of the SF424 (R&R).
Inclusion of Women, Minorities and Children in Research: The adequacy of plans to include subjects from both genders, all racial and ethnic groups (and subgroups), and children as appropriate for the scientific goals of the research will be assessed. Plans for the recruitment and retention of subjects will also be evaluated. See item 7 of the Research Plan component of the SF424 (R&R).
Care and Use of Vertebrate Animals in Research: If vertebrate animals are to be used in the project, the five items described under item 11 of the Research Plan component of the SF424 (R&R) will be assessed.
Biohazards: If materials or procedures are proposed that are potentially hazardous to research personnel and/or the environment, determine if the proposed protection is adequate.
2.B. Additional Review Considerations
Budget: The reasonableness of the proposed budget and the requested period of support in relation to the proposed research may be assessed by the reviewers. Is the percent effort listed for the PD/PI appropriate for the work proposed? Is each budget category realistic and justified in terms of the aims and methods?
Period of Support: The appropriateness of the requested period of support in relation to the proposed research.
2.C. Sharing Research Data
The reasonableness of the data sharing plan or the rationale for not sharing research data may be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score. The funding organization will be responsible for monitoring the data sharing policy. https://grants.nih.gov/grants/policy/data_sharing and https://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm. (See FAQ #13.)
2.D. Sharing Research Resources
NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (See the NIH Grants Policy Statement https://grants.nih.gov/archive/grants/policy/nihgps/part_ii_5.htm#availofrr and http://www.ott.nih.gov/policy/rt_guide_final.html). Investigators responding to this funding opportunity should include a sharing research resources plan addressing how unique research resources will be shared or explain why sharing is not possible.
Program staff will be responsible for the administrative review of the plan for sharing research resources.
The adequacy of the resources sharing plan will be considered by Program staff of the funding organization when making recommendations about funding applications. Program staff may negotiate modifications of the data and resource sharing plans with the awardee before recommending funding of an application. The final version of the data and resource sharing plans negotiated by both will become a condition of the award of the grant. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each Non-Competing Grant Progress Report (PHS 2590). See Section VI.3. Reporting.
3. Anticipated Announcement and Award Dates
Not applicable
1. Award Notices
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant. For details, applicants may refer to the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General.
A formal notification in the form of a Notice of Grant Award (NoA) will be provided to the applicant organization. The NoA signed by the grants management officer is the authorizing document. Once all administrative and programmatic issues have been resolved, the NoA will be generated via email notification from the awarding component to the grantee business official.
Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See also Section IV.5. Funding Restrictions.
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm) and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities (https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm).
3. Reporting
Awardees will be required to submit the Non-Competing Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.Section VII. Agency Contacts
We encourage your inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into three areas: scientific/research, peer review, and financial or grants management issues:
1. Scientific/Research and Financial/Grants Management Contacts:
Scientific/Research and Financial/Grants Management contacts for this program announcement are listed below.
Awarding Component
Scientific/Research Contact
Financial/Grants Mgmt. Contact
National Institute on Aging
Dr. Michael-David A.R.R. Kerns
Ms. Linda Whipp
National Institute on Alcohol Abuse and Alcoholism
Dr. Karen P. Peterson
Ms. Judy Fox
National Institute of Allergy and Infectious Diseases
Dr. Gregory Milman
Ms. Mary Kirker
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Dr. Cheryl Kitt
Ms. Melinda Nelson
National Institute of Biomedical Imaging and Bioengineering
Mr. Todd Merchak
Ms. Florence Turska
National Cancer Institute
Mr. Michael Weingarten
Mr. Ted Williams
National Institute of Child Health and Human Development
Dr. Louis A. Quatrano
Annette Hanopole
National Institute on Drug Abuse
Dr. Cathrine Sasek
Ms. Diana Haikalis
National Institute on Deafness and Other Communication Disorders
Dr. Lynn E. Luethke
Mr. Christopher P. Myers
National Institute of Dental and Craniofacial Research
Dr. Rosemarie Hunziker
Ms. Mary Daley
National Institute of Diabetes and Digestive and Kidney Diseases
Dr. Sanford A. Garfield
Ms. Helen Y. Ling
National Institute of Environmental Health Sciences
Dr. Jerrold J. Heindel
Mr. Dwight Dolby
National Eye Institute
Dr. Ralph Helmsen
Mr. William Darby
National Institute of General Medical Sciences
Dr. Peter Preusch
Ms. Patrice Molnar
National Heart, Lung, and Blood Institute
Ms. Susan Pucie
Ms. Suzanne White
National Human Genome Research Institute
Dr. Bettie J. Graham
Ms. Cheryl Chick
National Institute of Mental Health
Dr. Michael F. Huerta
Ms. Rebecca Claycamp
National Institute of Neurological Disorders and Stroke
Dr. Randall Stewart
Mr. Mike Loewe
National Institute of Nursing Research
Dr. Yvonne Bryan
Mr. Brian Albertini
National Center for Research Resources
Dr. Louise E. Ramm
Ms. Holly Atherton
National Center for Complementary and Alternative Medicine
Dr. Dr. Carol Pontzer
Mr. George Tucker, M.B.A.
National Center on Minority Health and Health Disparities
Mr. Vincent A. Thomas, Jr., MSW, MPA
Mr. Bryan Clark, MBA
National Library of Medicine
Dr. Charles Friedman
Mr. Dwight Mowery
Centers for Disease Control and Prevention (CDC)
Mr. Curtis Bryant
Ms. Sharron Orum
Food and Drug Administration (FDA)
Mr. Phillip Osborne
Ms. Tya Marks
Section VIII. Other Information
2. Peer Review Contacts:
Not applicable
Required Federal Citations
Use of Animals in Research:
Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (https://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act of 1985 (https://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.
Human Subjects Protection:
Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials, including physiologic toxicity and dose-finding studies (Phase I); efficacy studies (Phase II); efficacy, effectiveness and comparative trials (Phase III). Monitoring should be commensurate with risk. The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risks to the participants (NIH Policy for Data and Safety Monitoring, NIH Guide for Grants and Contracts, https://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Sharing Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why this is not possible (https://grants.nih.gov/grants/policy/data_sharing).
Investigators should seek guidance from their institutions on issues related to institutional policies and local IRB rules, as well as local, State and Federal laws and regulations, including the Privacy Rule. Reviewers will consider the data sharing plan but will not factor the plan into the determination of scientific merit or the priority score.
Access to Research Data through the Freedom of Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to provide access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are (1) first produced in a project that is supported in whole or in part with Federal funds and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this funding opportunity in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award.
Sharing of Model Organisms:
NIH is committed to support efforts that encourage sharing of important research resources including the sharing of model organisms for biomedical research (see https://grants.nih.gov/grants/policy/model_organism/index.htm). At the same time the NIH recognizes the rights of grantees and contractors to elect and retain title to subject inventions developed with Federal funding pursuant to the Bayh Dole Act (see the NIH Grants Policy Statement https://grants.nih.gov/archive/archive/grants/policy/nihgps_2003/index.htm). All investigators submitting an NIH application or contract proposal, beginning with the October 1, 2004 receipt date, are expected to include in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible. This will permit other researchers to benefit from the resources developed with public funding. The inclusion of a model organism sharing plan is not subject to a cost threshold in any year and is expected to be included in all applications where the development of model organisms is anticipated.
Inclusion of Women And Minorities in Clinical Research:
It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is available at https://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the SF424 (R&R) application; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.
Inclusion of Children as Participants in Clinical Research:
The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all clinical research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them.
All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects (https://grants.nih.gov/grants/funding/children/children.htm).
Required Education on the Protection of Human Subject Participants:
NIH policy requires education on the protection of human subject participants for all investigators submitting NIH applications for research involving human subjects and individuals designated as key personnel. The policy is available at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem Cells (hESC):
Criteria for federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov). It is the responsibility of the applicant to provide in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s) to be used in the proposed research. Applications that do not provide this information will be returned without review.
NIH Public Access Policy:
NIH-funded investigators are requested to submit to the NIH manuscript submission (NIHMS) system (http://www.nihms.nih.gov) at PubMed Central (PMC) an electronic version of the author's final manuscript upon acceptance for publication, resulting from research supported in whole or in part with direct costs from NIH. The author's final manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process.
NIH is requesting that authors submit manuscripts resulting from 1) currently funded NIH research projects or 2) previously supported NIH research projects if they are accepted for publication on or after May 2, 2005. The NIH Public Access Policy applies to all research grant and career development award mechanisms, cooperative agreements, contracts, Institutional and Individual Ruth L. Kirschstein National Research Service Awards, as well as NIH intramural research studies. The Policy applies to peer-reviewed, original research publications that have been supported in whole or in part with direct costs from NIH, but it does not apply to book chapters, editorials, reviews, or conference proceedings. Publications resulting from non-NIH-supported research projects should not be submitted.
For more information about the Policy or the submission process, please visit the NIH Public Access Policy Web site at http://www.nih.gov/about/publicaccess/ and view the Policy or other Resources and Tools including the Authors' Manual (http://www.nih.gov/about/publicaccess/publicaccess_Manual.htm).
Standards for Privacy of Individually Identifiable Health Information:
The Department of Health and Human Services (DHHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information", the "Privacy Rule", on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the DHHS Office for Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR Website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Furthermore, we caution reviewers that their anonymity may be compromised when they directly access an Internet site.
Healthy People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This PA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Authority and Regulations:
This program is described in the Catalog of Federal Domestic Assistance and is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified health professionals who have made a commitment to pursue a research career involving clinical, pediatric, contraception, infertility, and health disparities related areas. The LRP is an important component of NIH's efforts to recruit and retain the next generation of researchers by providing the means for developing a research career unfettered by the burden of student loan debt. Note that an NIH grant is not required for eligibility and concurrent career award and LRP applications are encouraged. The periods of career award and LRP award may overlap providing the LRP recipient with the required commitment of time and effort, as LRP awardees must commit at least 50% of their time (at least 20 hours per week based on a 40 hour week) for two years to the research. For further information, please see: http://www.lrp.nih.gov.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
Research (OER)
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.


text:
Wednesday, April 22, 2009
Braised Rabbit in Tomato-Wine Sauce
The dilemma was what to call it. "It" was a rabbit I'd braised in a wine and tomato broth to which mushrooms and pearl onions had also been added. I'd heard that rabbit tastes like chicken, so I decided to prepare it as I would a braised chicken. I had the ingredients I needed to make a sauce that resembled the one I use to make Chicken Marengo. I decided to go with that and, fortunately, it worked. Rabbit, by the way, doesn't taste like supermarket chicken. It's more like the dark meat of a free range chicken. It's not at all gamey and, while this will never be a favorite of mine, we'll have it again because Bob loves it. I'll be experimenting with sauces and techniques, so prepare yourselves for plethora of rabbit recipes. Bob was able to buy the rabbit at a local bodega that sells frozen game. Our rabbit was farm raised so I can't speak to the texture or flavor of a jackrabbit. This was really easy to prepare and comes recommended if you really want to cook a rabbit. I served it with rice pilaf. Polenta would also be a great accompaniment.
Braised Rabbit in Tomato-Wine Sauce with Mushrooms and Pearl Onions
1 2-1/2 to 3 pound rabbit, cut into pieces
1-1/2 teaspoons salt
1/2 teaspoon pepper
1/3 cup flour
1 tablespoon olive oil
3 tablespoons butter, divided use
2 tablespoons tomato paste
1 tablespoon minced garlic
1 cup dry white vermouth
1 (10.5-oz.) can condensed chicken broth, undiluted
1 bay leaf
1 teaspoon dried thyme
1 cup frozen pearl onions, thawed and patted dry
1 teaspoon sugar
1/2 pound sliced mushrooms
Parsley sprigs for garnish
1) Mist rabbit pieces with nonstick cooking spray. Season rabbit pieces with salt and pepper. Dredge if flour, shaking off excess.
2) Heat oil and two tablespoons butter in a large skillet over medium-high heat. Add rabbit pieces and saute until golden, about 4 minutes per side.
3) Add tomato paste, garlic, vermouth, chicken broth, bay leaf and thyme. Stir to combine. Bring to a boil, cover, reduce heat to medium and simmer for 45 minutes, turning pieces once or twice.
4) Meanwhile, melt reserved 1 tablespoon butter in a large saute pan. Add onions, sprinkle with 1 tablespoon sugar and cook until lightly brown. Add mushrooms and brown.
5) Add onions and mushrooms to rabbit; cook, covered, for 15 minutes longer. Adjust seasoning with salt and pepper to taste.
4) Transfer contents of skillet to a serving platter. Tent with foil to keep warm. Rapidly boil stock until thickened. Spoon over rabbit. Garnish with parsley sprigs. Yield: 4 servings.
27 comments :
- Farmer Jo said...
My hubby is so happy you posted this recipe. Where did you buy the rabbit?
- April 22, 2009 at 12:18 AM
- Mary Bergfeld said...
Jo, we have a Mexican grocer who stocks frozen game and rabbit. I think you should be able to get it in Portland. Check with family owned grocery stores in Mexican or Italian neighborhoods.
- April 22, 2009 at 12:25 AM
- Jaime and Jen DISH said...
I have never had rabbit and honestly, I probably will never, ever. I do have to say that I would TOTALLY try the sauce over chicken though because it does look amazing.
- April 22, 2009 at 2:51 AM
- Sam Hoffer / My Carolina Kitchen said...
We're very fond of rabbit, or lapin as the French call it. Also love Chicken Marengo so I can understand how they go well together. We had rabbit a couple of weeks ago and I used a Chasseur sauce which is similar to Marengo with mushrooms and onions and it turned out great. I can't wait to tell my husband I have a new lapin recipe - thanks so much.
- April 22, 2009 at 6:37 AM
- Julia said...
Totally not worth the effort, but totally fun is whack of wabbit... I mean, Rack of Rabbit. The bones are so tiny and cute!
This looks great and look forward to seeing more neat ideas for rabbit.
- April 22, 2009 at 6:49 AM
- Schnitzel and the Trout said...
I grew up eating rabbit baked in wine sauce and whenever it is on the menu in Europe, I order it. Just love it. The small bones which can splinter are often not appetizing, but it is a marvelous meat and I am really surprised it is not offered more in America. I'd be happy to sit down and enjoy this meal with you.
- April 22, 2009 at 7:10 AM
- Ginger said...
Hi Mary,
I have never had Rabbit but would really like to try it. Your sauce sounds exceptionally delicious!!
- April 22, 2009 at 7:41 AM
- Ning said...
What is it with men that they are so happy with eating rabbit? My Hubby also loves rabbit. Fortunately, the Chinese believe that rabbits are good meat, nutritious for the body. Unfortunately, my kids would not touch the meat because they have a pet rabbit :)
- April 22, 2009 at 8:20 AM
- Katherine Roberts Aucoin said...
The picture is gorgeous but I don't think I would be able to eat rabbit. However, I would love to try this recipe on chicken, my mouth was watering reading the indgredients and I have everything at home to make this...might be something to try tomorrow night!
- April 22, 2009 at 8:45 AM
- Netts Nook said...
I love rabbit it is so hard to find here also. Wow what a dish. You are always at the top of my list.
- April 22, 2009 at 9:54 AM
- SleightGirl said...
I love rabbit...and that looks really yummy!
- April 22, 2009 at 10:57 AM
- Mary Bergfeld said...
SleightGirl, it is really easy. I just wanted to welcome you to One Perfect Bite. I hope you'll become a regular visitor.
- April 22, 2009 at 11:06 AM
- La Bella Cooks said...
I have yet to ever try rabbit but it does look amazing.
- April 22, 2009 at 1:46 PM
- The Blonde Duck said...
I've never had rabbit. I'm intrigued.
- April 22, 2009 at 1:50 PM
- NKP said...
I have never had rabbit either, I think it needs a marketing board to change the name for the meat, like they did for beef and pork.
One day I will be brave and give it a shot, I admire you for stepping outside your normal comfort zone.
- April 22, 2009 at 1:53 PM
- Pam said...
The sauce sounds amazing but I think I'll make it with chicken - I can't help but picture a cute little bunny and I just don't think I could eat one.
- April 22, 2009 at 4:04 PM
- noble pig said...
I have never had rabbit, I have to admit I'm afraid. It looks beautiful though.
- April 22, 2009 at 4:12 PM
- Heather S-G said...
This is a gorgeous dinner! I like rabbit, don't eat it often...but I'd love to try it like this!
- April 22, 2009 at 7:03 PM
- Karen said...
I'd love to try rabbit and this dish looks delicious. About the only chance I have of getting rabbit up here is if one happens into my garden one day. LOL
- April 22, 2009 at 7:51 PM
- Laura said...
Looks fantastic--I love braised meat, although I have never had rabbit either.
- April 22, 2009 at 11:26 PM
- Jamie said...
This is a gorgeous dish and what I not only love to make, but love to eat. I love rabbit, though the family isn't crazy about it, but this would be such a treat!
- April 23, 2009 at 3:52 AM
- Snake Charmer said...
omg that looks so very good
- April 23, 2009 at 7:07 AM
- Lori said...
That looks really delicious. I wonder if I would be so brave. I tell my husband that we have to get a trap because if times get tough, real tough, economically we will be giving the rabbits in our yard a run for their money!
- April 23, 2009 at 4:16 PM
- Diary From Africa said...
I've never eaten or cooked rabbit before, but it's something I'd like to try if I ever have the chance. It looks very interesting !
- April 25, 2009 at 3:24 PM
- 3timesamom said...
My husband hunts rabbit, so we do eat rabbit occasionally. Although it doesn't taste exactly like chicken, it is very similar. If you are preparing jack rabbit yourself, it should be soaked in salt water overnight before freezing or preparing. This will take the "gamey" taste away and will also make the meat less chewy. Your dish looks great, and I will be trying this recipe soon! thank you!
- April 28, 2009 at 12:01 PM
- Mary Bergfeld said...
Welcome 3timesamom and thanks you for the tips on jack rabbit. I hope you'll visit with us often.
- April 28, 2009 at 12:08 PM
- Melissa and Zack said...
I can picture the look on Dad's face while he holds up the rabbit looking so proud of himself!!
- April 30, 2009 at 2:01 PM

subset: commoncrawl


text: Posted on November 20, 2015 by nieves You are logged in: Edit this product | Add images 3 x 5 E-POLY EL SALVADOR w/SEAL O/D FLAG This item usually takes about 5 days to ship Item no. 031324 Your Cost: $24.00 How many: this product does not ship free Still have questions about this product? Ask your question here Your email


text:
The BR series coilovers use a large 46mm diameter piston in a 53mm diameter damper body to maximise oil capacity. As the damper unit operates the oil contained within heats up. The viscosity of oil changes as its temperature varies which can lead to changes in the damping characteristics of the unit.
BC Racing only use a very high quality oil with their coilovers but go that extra mile to maximise performance and build their BR range with a large 53mm diameter damper body. This increases the capacity of the unit which increases the volume of oil contained which in turn reduces the peak temperature and so significantly improves damper performance.
*Fits European models only not US
**Dispatch in 3-9 working days


text:
3X Nano Glass Screen Protectors for Garmin Forerunner 965Nano Glass AirGlass, exclusively offered by BROTECT It's 2x thinner and lighter than tempered glass protectors and more flexible than all other glass protectors on the market, while still offering super strong anti-scratch hardness of thicker tempered screen protectors. Its Ultra-Light properties and High-Transparency ensure you have a clear, unobstructed, sharp view of the display, while maintaining touch-screen and multi-touch sensitivity. An additional Anti-Fingerprint layer helps prevent dirt and fingerprint smears. The adhesive layer ensures that the screen protector glides smoothly and effortlessly onto your Garmin Forerunner 965 for a bubble-free, easy installation. Please note: Because of the curved edges of some displays, some of our protectors are cut deliberately slightly smaller than the display.
Ships with:
- 3X Nano Glass Screen Protectors for Garmin Forerunner 965
- Application Kit (Polishing Cloth/Alcohol Wipe/Smoothing Card/Aligning Kit)
- Application Instructions
Nano Glass Screen Protectors
Our Nano-Glass Screen Protectors are made up of a number of layers, providing a high level of protection, whilst maintaining clarity and fingerprint-resistance with its oleophobic coating.
The multi-layered Nano-Glass also allows it to be more flexible than traditional slate-style tempered glass screen protectors, which in turn, improves impact resistance and removes the risk of shatters and sharp glass shards.
More Screen Protectors for Garmin Forerunner 965
Worthy extras for Garmin Forerunner 965
Get the most out of your device, We've got some other basics you shouldn't be without. Add to your cart and save when you buy a screen protector from us and pay no more in shipping!See more Accessories
Note: Garmin, Garmin forerunner 965 may be trademarks, owned by respective trademark owner/s. No endorsements have been made from the trademark owner/s or device manufacturers, and are used for referential and compatibility purposes only, unless otherwise stated. Learn more.


text:
|Trouble cutting and pasting your resume into the window provided
|Resume doesn't look like it will fit within the text box provided
How your resume looks in the text box is not necessarily how it will look when an employer views it. Be sure to align the bullets, tabs and spacing to ensure a well-formatted view for the recruiters.
|Using HTML when formatting your resume within the text box
Do not use HTML when submitting your resume. Your resume will be viewed by recruiters with widely varying screen dimensions, including Palm Pilots. Your resume might be converted into straight ASCII text and imported into a database or resume management software.
|Targeting your job search
You can fine tune your job search by using specific keywords in the Keyword Search. If these keywords are in any part of a job, the search will return those jobs.
Example keywords: marketing, business administration
Example: Business Administration
Example: Business Administration and marketing and entry level
|Selecting more than one choice in a list box
|To select multiple choices in a drop down box, hold down the CTRL ("Control") key while clicking the options with the mouse. Use the SHIFT key if you're using a Macintosh.
|Printing your resume
|When you are reviewing your resume, click into that frame. From your browser's menu, select 'File' and 'Print - only selected frame.'
|Changing your username and password
|You will not be able to change your username or password. If you lose your password, you can click on the "Forgot Password" button next to the password box on the login page. If you have forgotten your username, you will need to register again.
|How your Job Spy work
|Routinely, your Job Spy will search the job database. If a new job has been added that contains your Job Spy criteria, that job will be emailed to you! Enter the keywords that a job should contain in the "Keyword(s)" box. Create a memorable name for your Job Spy.


text:
Edison, NJ -- (SBWIRE) -- 12/16/2020 -- A new business intelligence report released by HTF MI with title "Global Enterprise Video Platform Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)" is designed covering micro level of analysis by manufacturers and key business segments. The Global Enterprise Video Platform Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are Brightcove, Vbrick, Comcast Technology Solutions, Haivision, Ooyala & Kaltura.
What's keeping Brightcove, Vbrick, Comcast Technology Solutions, Haivision, Ooyala & Kaltura Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by HTF MI
Get Free Sample Report + All Related Graphs & Charts @ : https://www.htfmarketreport.com/sample-report/2986632-global-enterprise-video-platform-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026
Market Overview of Global Enterprise Video Platform
If you are involved in the Global Enterprise Video Platform industry or aim to be, then this study will provide you inclusive point of view. It's vital you keep your market knowledge up to date segmented by Applications [Corporate, Government, Education, Media and Entertainment & Others], Product Types [, Video Streaming, Web Conferencing, Video Conferencing & Others] and major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.
This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market along with impact of economic slowdown due to COVID.
Furthermore, the years considered for the study are as follows:
Historical year – 2014-2019
Base year – 2019
Forecast period** – 2020 to 2026 [** unless otherwise stated]
**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.
Enquire for customization in Report @: https://www.htfmarketreport.com/enquiry-before-buy/2986632-global-enterprise-video-platform-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026
The titled segments and sub-section of the market are illuminated below:
The Study Explore the Product Types of Enterprise Video Platform Market: , Video Streaming, Web Conferencing, Video Conferencing & Others
Key Applications/end-users of Global Enterprise Video PlatformMarket: Corporate, Government, Education, Media and Entertainment & Others
Top Players in the Market are: Brightcove, Vbrick, Comcast Technology Solutions, Haivision, Ooyala & Kaltura
Region Included are: North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile & Others
Important Features that are under offering & key highlights of the report:
– Detailed overview of Enterprise Video Platform market
– Changing market dynamics of the industry
– In-depth market segmentation by Type, Application etc
– Historical, current and projected market size in terms of volume and value
– Recent industry trends and developments
– Competitive landscape of Enterprise Video Platform market
– Strategies of key players and product offerings
– Potential and niche segments/regions exhibiting promising growth
– A neutral perspective towards Enterprise Video Platform market performance
– Market players information to sustain and enhance their footprint
Read Detailed Index of full Research Study at @ https://www.htfmarketreport.com/reports/2986632-global-enterprise-video-platform-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026
Major Highlights of TOC:
Chapter One: Global Enterprise Video Platform Market Industry Overview
1.1 Enterprise Video Platform Industry
1.1.1 Overview
1.1.2 Products of Major Companies
1.2 Enterprise Video Platform Market Segment
1.2.1 Industry Chain
1.2.2 Consumer Distribution
1.3 Price & Cost Overview
Chapter Two: Global Enterprise Video Platform Market Demand
2.1 Segment Overview
2.1.3 Other
2.2 Global Enterprise Video Platform Market Size by Demand
2.3 Global Enterprise Video Platform Market Forecast by Demand
Chapter Three: Global Enterprise Video Platform Market by Type
3.1 By Type
3.2 Enterprise Video Platform Market Size by Type
3.3 Enterprise Video Platform Market Forecast by Type
Chapter Four: Major Region of Enterprise Video Platform Market
4.1 Global Enterprise Video Platform Sales
4.2 Global Enterprise Video Platform Revenue & market share
Chapter Five: Major Companies List
Chapter Six: Conclusion
Complete Purchase of Latest Version Global Enterprise Video Platform Market Study with COVID-19 Impact Analysis @ https://www.htfmarketreport.com/buy-now?format=1&report=2986632
Key questions answered
- What impact does COVID-19 have made on Global Enterprise Video Platform Market Growth & Sizing?
- Who are the Leading key players and what are their Key Business plans in the Global Enterprise Video Platform market?
- What are the key concerns of the five forces analysis of the Global Enterprise Video Platform market?
- What are different prospects and threats faced by the dealers in the Global Enterprise Video Platform market?
- What are the strengths and weaknesses of the key vendors?
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
Connect with us at LinkedIn | Facebook | Twitter


text:
Show everyone that you are a die-hard fan by hanging up this 3-foot x 5-foot NFL flag. This officially licensed flag is made of durable, 100% polyester and is designed with 2 heavy-duty metal grommets so it is easy to hang. This high-quality flag is decorated in the team colors and proudly displays the official team graphics in the center.
Price : $28.75
Brand : Fremont Die


text:
American Gastropub, Catering, Events
Click here for Farmingdale Discounts!
Click here for Farmingdale's Map
Join Today
Start benefiting from your Chamber membership today. Sign up today and get your business more exposure. Connect and grow your business with the Chamber.
Join Today
Farmingdale Chamber of Commerce
PO Box 1166, Farmingdale, NY 11735
© Copyright 2023 Farmingdale Chamber of Commerce. All Rights Reserved. Site provided by GrowthZone - powered by ChamberMaster software.


text:
Grievance Procedure for the College of Liberal Arts and Sciences
To articulate the procedures for hearing grievances arising within the College of Liberal Arts and Sciences.
Faculty and students within the College of Liberal Arts & Sciences.
Staff in the College of Liberal Arts & Sciences follow the University Staff Grievance Procedure.
Pursuant to Article XII of the University Senate Code and the University Senate Rules and Regulations of the University of Kansas, Lawrence, the College Office establishes the following procedure to hear grievances arising within the College of Liberal Arts and Sciences. Certain subordinate units that report to the College must establish unit grievance procedures. Other subordinate units may do so. If a subordinate unit has a grievance procedure, grievances arising within the subordinate unit or its subunits must be heard under the subordinate unit's grievance procedure unless exceptional circumstances, as determined by the College, make it more appropriate for those grievances to be heard at the College level. Appeal of a grievance heard at a subordinate unit level is to the Judicial Board, not to the This procedure shall not be used to hear disputes assigned to other hearing bodies under USRR Article VI, Section 4.
For disputes involving alleged academic misconduct, see the College of Liberal Arts and Sciences policy on academic misconduct. For alleged violations of student rights, the initial hearing normally will be at the unit level. There is an option to hold an initial hearing at the Judicial Board level if both parties agree, or either party petitions the Judicial Board chair to have the hearing at the Judicial Board level and the petition is granted. The petition must state why a fair hearing cannot be obtained at the unit level; the opposing party has an opportunity to respond to the petition (USRR 188.8.131.52).
Except as provided in USRR 6.5.4, no person shall be disciplined for using the grievance procedure or assisting another in using the grievance procedure.
The College Office shall provide a copy of this procedure to anyone who requests it.
1. To start the grievance process, the complainant must submit a written grievance to the College Office. The complaint shall contain a statement of the facts underlying the complaint and specify the provision(s) of the Faculty Code of Conduct, University Senate Code, the University Senate Rules and Regulations, the Code of Student Rights and Responsibilities, or other applicable rule, policy, regulation, or law allegedly violated. The complaint shall also indicate the witnesses or other evidence relied on by the complaining party, and copies of any documents relevant to the complaint shall be attached to the complaint.
2. At the time the complaint is submitted to the College, the complaining party shall provide a copy of the complaint, with accompanying documents, to the respondent(s).
3. Upon receipt of the complaint, the College Office shall contact the respondent to verify that the respondent has received a copy of the complaint and to provide the respondent with a copy of these procedures.
4. Pursuant to University Senate Code Article XII.2, a respondent has the privilege of remaining silent and refusing to give evidence in response to a complaint. The respondent also has the right to respond and give evidence in response to the complaint.
5. The respondent shall submit a written response to the College Office within 14 calendar days of receiving the complaint. The response shall contain the respondent's statement of the facts underlying the dispute as well as any other defenses to the allegations in the complaint. The response shall also identify the witnesses or other evidence relied on by the respondent and shall include copies of any documents relevant to the response. The respondent shall provide a complete copy of the response to the complaining party.
6. Upon receipt of the response, the College Office shall contact the complaining party to verify that a copy of the response has been provided.
7. Upon receiving the complaint and response, or if the respondent fails to respond within the 14-day time period, the Dean shall appoint a faculty committee selected from the current members of standing committees of the College to consider the complaint. The committee members shall be disinterested parties who have not had previous involvement in the specific situation forming the basis of the complaint.
8. Pursuant to USRR 22.214.171.124, the chair of the committee may contact other hearing bodies within the University to determine whether a grievance or complaint involving the underlying occurrence or events is currently pending before or has been decided by any other hearing body.
9. Time limits. To use this procedure, the complainant must file the written complaint with the College Office within six months from the action or event that forms the basis of the complaint. The six-month time period shall be calculated using calendar days (including weekends and days during which classes are not in session).
10. Upon receiving the complaint, if the chair of the committee determines that the any of the following grounds exist, he or she may recommend to the Dean that the complaint be dismissed without further proceedings. The grounds for such dismissal are: (a) the grievance or another grievance involving substantially the same underlying occurrence or events has already been, or is being, adjudicated by proper University procedures; (b) the grievance has not been filed in a timely fashion; (c) the Dean lacks jurisdiction over the subject matter or any of the parties; (d) the grievance fails to allege a violation of a University rule; (e) the party filing the grievance lacks standing because he or she has not suffered a distinct injury as a result of the challenged conduct and has not been empowered to bring the complaint on behalf of the University; or (f) the party filing the grievance has been denied the right to file grievances pursuant to USRR 6.5.4.
11. If the chair of the committee determines that a grievance on its face properly should be heard by another body, the chair will recommend that the Dean send the grievance to the appropriate hearing body without further proceedings in the Dean's Office. The Dean will send a copy of the referral to the complainant(s) and any responding parties.
12. Prior to scheduling a hearing, the parties shall participate in mediation of the dispute unless either party waives mediation. Mediation shall be governed by USRR 6.2.3.
13. If mediation is successful, the mediator will forward to the Dean, the committee chair, and all parties a letter describing the outcome of the mediation and the terms upon which the parties have agreed to resolve the dispute. This letter shall be a recommendation to the Dean. The Dean will notify the mediator, the committee chair, and the parties that the recommendation has been accepted, modified, or rejected.
14. If mediation is not successful, the mediator will notify the Dean, the committee chair, and the parties that mediation has terminated. If mediation is not successful, or if it is waived by either party, the grievance committee will schedule a hearing no later than 30 calendar days from the written submission of the complaint. The 30-day period may be extended for good cause as determined by the chair of the committee. The 30-day period shall be suspended during the mediation process. The hearing will be closed unless all parties agree that it shall be public.
15. Each party may represent himself or herself or be represented by an advisor or counsel of his or her choice.
16. Each party has the right to introduce all relevant testimony and documents if the documents have been provided with the complaint or response.
17. Each party shall be entitled to question the other party's witnesses. The committee may question all witnesses.
18. Witnesses other than parties shall leave the hearing room when they are not testifying.
19. The chair of the committee shall have the right to place reasonable time limits on each party's presentation.
20. The chair of the committee shall have the authority and responsibility to keep order, rule on questions of evidence and relevance, and shall possess other reasonable powers necessary for a fair and orderly hearing.
21. The hearing shall not be governed by the rules of evidence, but the chair of the committee may exclude information he or she deems irrelevant, unnecessary, or duplicative. Statements or admissions made as part of the mediation process are not admissible.
22. The committee will make an audiotape of the hearing but not of the deliberations of the committee. The audiotape will be available to the parties, their authorized representatives, the committee and the Dean. If a party desires a copy of the audiotape or a transcript of the tape, that party will pay for the cost of such copy or transcript. In the event of an appeal, the audiotape will be provided to the appellate body as part of the record of the case.
23. After the presentation of evidence and arguments, the committee will excuse the parties and deliberate. The committee's decision will be a written recommendation to the Dean. The committee shall base its recommendations solely upon the information presented at the hearing.
24. The committee will send its written recommendation to the Dean and the parties as soon as possible and no later than 14 calendar days after the end of the hearing.
25. Within 14 calendar days of receiving the committee recommendation, the Dean will notify the parties of the acceptance, modification, or rejection of the recommendation. The Dean will advise the parties of the procedure available to appeal the decision.
Associate Dean for Administrative Affairs
College of Liberal Arts and Sciences
12/09/2021: Fixed broken link.
01/17/2018: Updated "applies to" to acknowledge new process for staff
06/22/2017: Updated contact information
10/01/2015: Fixed anchor links; set to open new window.
09/28/2015: Corrected "Article" links and added links that were missing.
3/2009: Approved by Erin Spiridigliozzi


text:
South Carolina Cost-Efficient, Results-Oriented Civil Litigation Attorneys
Helping businesses and individuals successfully resolve disputes
When legal disputes disrupt your business or personal life, having a committed, knowledgeable attorney to zealously advocate on your behalf brings comfort and peace of mind. Minor, Haight & Arundell, P.C. represents South Carolina businesses, families and individuals in litigation, arbitration and mediation. We can help you with all types of general civil litigation in state and federal courts, including:
- Business litigation
- Breach of contract
- Property damage
- Personal injury claims
- Insurance claims
- Construction litigation
- Consumer litigation
- Products liability
- Product defects
- Torts
Put a strong, determined litigator to work for you
Minor, Haight & Arundell, P.C. knows your time is valuable. That is why we stress efficiency throughout the process of resolving your disputes. We offer our clients:
- Individual attention — When you retain our law firm, you receive the care, time and attention you deserve.
- A more cost-efficient model — We constantly seek ways to cut your costs while maintaining the high level of legal services you expect and deserve.
- Integrity — Our trial attorneys provide you with straightforward, honest answers to all of your questions and ensure you fully understand the litigation process and what to expect as your case moves forward. Our clients rely on us to help them set realistic expectations.
- A focus on success — We always have your best interest in mind. If protracted litigation is the only solution to achieve the proper outcome, we are ready. If settling your case early on will achieve the best result, we take the time to explain why we believe it is in your best interest to settle instead of engaging in lengthy litigation.
Ready for trial
Minor, Haight & Arundell, P.C. has the determination, tenacity and skill required to successfully litigate your case when litigation provides the best means of resolving your legal issues. Our professional courtroom demeanor and meticulous preparation give us an edge as assertive, strategic advocates.
Contact an assertive Hilton Head Island, South Carolina litigation lawyer you can trust
Call Minor, Haight & Arundell, P.C. at 843-785-8040 or contact us online to schedule your free initial consultation.


text:
Wednesday, January 16, 2013
23 Presidential executive actions regarding gun violence
In the wake of the Connecticut school shootings and renewed interest in gun rights versus gun control, President Barack Obama announced 23 executive actions to curb gun violence. They are:
1. Issue a Presidential Memorandum to require federal agencies to make relevant data available to the federal background check system.
2. Address unnecessary legal barriers, particularly relating to the Health Insurance Portability and Accountability Act, that may prevent states from making information available to the background check system.
3. Improve incentives for states to share information with the background check system.
4. Direct the Attorney General to review categories of individuals prohibited from having a gun to make sure dangerous people are not slipping through the cracks.
5. Propose rulemaking to give law enforcement the ability to run a full background check on an individual before returning a seized gun.
6. Publish a letter from ATF to federally licensed gun dealers providing guidance on how to run background checks for private sellers.
7. Launch a national safe and responsible gun ownership campaign.
8. Review safety standards for gun locks and gun safes (Consumer Product Safety Commission).
9. Issue a Presidential Memorandum to require federal law enforcement to trace guns recovered in criminal investigations.
10. Release a DOJ report analyzing information on lost and stolen guns and make it widely available to law enforcement.
11. Nominate an ATF director.
12. Provide law enforcement, first responders, and school officials with proper training for active shooter situations.
13. Maximize enforcement efforts to prevent gun violence and prosecute gun crime.
14. Issue a Presidential Memorandum directing the Centers for Disease Control to research the causes and prevention of gun violence.
15. Direct the Attorney General to issue a report on the availability and most effective use of new gun safety technologies and challenge the private sector to develop innovative technologies.
16. Clarify that the Affordable Care Act does not prohibit doctors asking their patients about guns in their homes.
17. Release a letter to health care providers clarifying that no federal law prohibits them from reporting threats of violence to law enforcement authorities.
18. Provide incentives for schools to hire school resource officers.
19. Develop model emergency response plans for schools, houses of worship and institutions of higher education.
20. Release a letter to state health officials clarifying the scope of mental health services that Medicaid plans must cover.
21. Finalize regulations clarifying essential health benefits and parity requirements within ACA exchanges.
22. Commit to finalizing mental health parity regulations.
23. Launch a national dialogue led by Secretaries Sebelius and Duncan on mental health.
No comments:
Subscribe to: Post Comments (Atom)


text:
- back to Rates
- verified by Scott Brooks, MBA, CFP® Editor
company Information
Delaware Life
Fixed annuities are for conservative investors who want safety, security, and guarantees.
You will preserve your principal and earn a fixed rate of return.
You might hear fixed annuities also called CD-like annuities or multiple-year guarantee annuities (MYGA's).
If you are sensitive to loss and don't want to lose a penny, a fixed annuity might be a good fit for some of your savings.
Read our educational articles on fixed annuities to learn more.
Guaranteed Rate Lock Period:
The rate is locked for 14 days from the date of application. If the funds are received after that period the rate might be subject to change and will be the rate in effect at that time.
what we like
- No surprises because you know what you will earn
- Percentage of balance withdrawals
- Lower agent commission
- Short 3 Year Term
- RMD Friendly
what we don't like
- Higher Rated Carriers Available
- Possible market value adjustment on withdrawals
Have a Question?
Schedule A Call
Apply Online
When You Are Ready
*Please provide an investment amount before applying.
Guaranteed Returns
Choose an investment amount and we'll show you how much you can earn.
|$ ?
|$ ?
|$ ?
|$ ?
|$ ?
|$ ?
|$ ?
|$ ?
|$ ?
|$ ?
|$ ?
|$ ?
Surrender Charge Schedule
Surrender charges are a penalty charged to early withdrawals of annuity contract. They are a percentage of the withdrawal amount, decrease over time, and go to zero when the term ends.
percentage charged to withdrawal
market-value adjustment (MVA)
A market value adjustment is basically an additional charge or credit for taking money out early from an annuity.
They allow companies to pay a higher rate and make longer-term investments.
MVAs only affect you if you withdraw funds early. If you own the contract to maturity, they do not apply.
other Information
|S&P rating
|BBB+ Good (8th of 21 ratings)
|phone number
|(877) 253-2323
|Product brochure
|1.0-2.0%. We are paid from the insurance company general fund. It is not deducted from your account value. 100% of your money is working for you from day one. We could earn a higher commission based on sales volume and taking a more active role in the application process.
|Rate Effective Date
|December 5th 2023
|premium Type
|Single Premium Annuity
|account Type
|Personal, Traditional IRA, Roth IRA, SEP-IRA, SIMPLE-IRA, 403(b).
|Not available in
|options at
30 Days prior to the end of your contract term, you will have the option to choose from the following.
1. Withdrawal any amount free of charges and fees.
|death benefit provision
|If you pass away before the end of your annuity contract, your beneficiaries will receive the accumulated policy value. This value will include all interest you have earned and be passed without any charges or fees.
|Annuities typically grow tax-deferred. If you withdrawal money that has never been taxed, withdrawals are 100% taxable. Non-qualified withdrawals have been taxed already, so only interest is taxed. This is called an exclusion ratio. Interest would be taxed, but the principal would not. Please work with a qualified specialist.
|surrender schedule
8%, 7%, 6%
|free-look period
|30 Days
|market value adjustment


text:
Dylan Metal Sign, Wall Art For Popular Girl's Name, Popular Boy's Name
Our Dylan metal sign is affordable art for your child's room, boy's room, girl's room, nursery, or baby shower. This white wall plaque has black accents and was designed in the industrial style.
- 100% made in the USA
- Free Shipping
- Free returns
- Featuring a durable, gloss coating that renders crisp, vibrant colors.
- Each unframed sign has a hole in each corner for easy hanging.
- Framed signs feature an open back for instant hanging on a nail or hook.
Made of Steel
Made of Steel
This sign is made of steel, a material that is famously durable and corrosion resistant.
Free Shipping!
Free Shipping!
We offer free shipping by USPS PRIORITY MAIL to all 50 of the United States of America, its territories and possessions, APOs, FPOs, DPOs, and the United Nations, NY. We do not ship internationally from this site. For international orders please contact email@example.com.
Free Returns!
Free Returns!
We have a 30-day return policy, which means you have 30 days after receiving your item to request a return.
To be eligible for a return, your item must be in the same condition that you received it, unworn or unused, with tags, and in its original packaging. You'll also need the receipt or proof of purchase.
Certain types of items cannot be returned, like, custom products (such as special orders or personalized items).
Unfortunately, we cannot accept returns on sale items or gift cards.
See our Refund Policy for details.


text:
with Courtesy of Miami Open Realty, LLC - Data updated on
Condoideas.com is not responsible for the accurancy of the information listed above. The data relating to real estate for sale on this website comes in part from the Internet Data Exchange Program and the South East Florida Regional MLS and is provided here for customers personal, non-commercial use, it may not be used for any purpose other than to identify prospective properties consumers may be interested in purchasing. Real Estate listings held by brokerage firms other than the office owning this website are marked with the IDX logo. Data provided is deemed reliable but not guaranteed.